Quality of life in patients with K-RASwild-type colorectal cancer-Reference-Cited by-同舟云学术

Quality of life in patients with K-RASwild-type colorectal cancer

Published:2013-10-11 Issue:2 Volume:120 Page:181-189
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ringash Jolie¹,Au Heather-Jane²,Siu Lillian L.¹,Shapiro Jeremy D.³,Jonker Derek J.⁴,Zalcberg John R.⁵,Moore Malcolm J.¹,Strickland Andrew⁶,Kotb Rami⁷,Jeffery Mark⁸,Alcindor Thierry⁹,Ng Siobhan¹⁰,Salim Muhammad¹¹,Sabesan Sabe¹²,Easaw Jay C.¹³,Shannon Jenny¹⁴,El-Tahche Fabyolla¹⁵,Walters Ian¹⁶,Tu Dongsheng¹⁷,O'Callaghan Christopher J.¹⁷, ,

Affiliation:

1. Princess Margaret Cancer Centre and University of Toronto; Toronto Ontario Canada

2. Cross Cancer Institute; Edmonton Alberta Canada

3. Cabrini Hospital and Monash University; Melbourne Victoria Australia

4. The Ottawa Hospital and the University of Ottawa; Ottawa Ontario Canada

5. Peter MacCallum Cancer Centre; University of Melbourne; Melbourne Victoria Australia

6. Monash Medical Centre and Monash University; Melbourne Victoria Australia

7. Sherbrooke University Medical Center; Sherbrooke Quebec Canada

8. Christchurch Hospital; Christchurch South Island New Zealand

9. McGill University; Montreal General Hospital; Montreal Quebec Canada

10. St John of God Hospital; Subiaco Western Australia Australia

11. Allan Blair Cancer Centre; Regina Saskatchewan Canada

12. Townsville Hospital; Townsville Queensland Australia

13. Tom Baker Cancer Centre; Calgary Alberta Canada

14. Nepean Hospital; Sydney New South Wales Australia

15. National Health and Medical Research Council Clinical Trials Centre; University of Sydney; Sydney New South Wales Australia

16. Bristol-Myers Squibb; Wallingford Connecticut

17. NCIC Clinical Trials Group; Queen's University; Kingston Ontario Canada

Funder

Canadian Cancer Society Research Institute

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28410/fullpdf

Reference17 articles.

2. K-ras mutations and benefit from cetuximab in advanced colorectal cancer;Karapetis;N Engl J Med.,2008

3. Cetuximab for the treatment of colorectal cancer;Jonker;N Engl J Med.,2007

4. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy;Garrett;Br J Cancer.,2011

5. Ayers M Awad M Malone D Correlation between k-ras status and efficacy results from a phase I/II study of brivanib alaninate in combination with cetuximab in patients (pts) with advanced or metastatic colorectal cancer (CRC) 2009

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions;Statistical Methods in Medical Research;2023-06-20

2. A Bayesian approach for two‐stage multivariate Mendelian randomization with mixed outcomes;Statistics in Medicine;2023-03-30

3. Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review;Cancers;2023-02-10

4. Quality of Life Outcomes in Stage IV Colorectal Cancer;Clinics in Colon and Rectal Surgery;2023-02-08

5. Regulated cell death in cancer: from pathogenesis to treatment;Chinese Medical Journal;2022-08-10